Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > REGULATORY
REGULATORY
- CSIMC Approves Plans for FY2013 Market Price Survey of Similar Size as 2 Years Ago
June 14, 2013
- CSIMC Expert Subcommittee: Reps Agree on Need to Redress Price Variations of Generics
June 13, 2013
- Japan’s Target Drug Market Size Revised Up to 12.8 Trillion Yen in 2020: Growth Strategy
June 13, 2013
- Reprocessing of Expired Anti-Influenza Drugs to Be Considered “If Necessary”
June 13, 2013
- Only About 50% of Doctors Aware of ADR Relief System: PMDA
June 12, 2013
- Half of Patients Unaware of New Anticoagulants: Healthy Japan 21 Promotion Forum Survey
June 11, 2013
- Expert Subcommittee to Begin Discussions on Next Year’s NHI Price Revision on June 12
June 11, 2013
- Director Kamada of HPB’s Economic Affairs Division Calls for Cooperation in Promoting Distribution Reform
June 11, 2013
- Bill to Amend PAL Unlikely to Be Enacted in Current Diet Session
June 10, 2013
- MHLW to Establish “PMDA-WEST” in Kansai Region in October
June 10, 2013
- Council Announces “Comprehensive STI Strategy” to Create One Trillion Yen Market for Regenerative Medicine by 2030
June 10, 2013
- Japan Set to Perk Up R&D to Expand Drug Market to 9 Trillion Yen in 2020
June 7, 2013
- MHLW Asks Industry Organization to Take Steps to Ensure Proper COI Management in Response to Diovan Scandal: HPB Director-General at Diet
June 7, 2013
- Abe Vows to Lift Ban on Online OTC Drug Sales; MHLW to Form Panel to Verify Safety
June 6, 2013
- Novartis Pharma Taking Steps to “Clean Up Its Act” in Wake of Diovan Scandal: Minister of Health Tamura
June 5, 2013
- Study Group Fails to Reach Agreement on Online Sales of OTC Drugs; Final Report to Collate Different Views
June 4, 2013
- Provisional Measure Allowing Online Sales of Class 2 and 3 OTC Drugs to Be Extended to End of 2013: MHLW
June 4, 2013
- MHLW to Look into Correlations of Pediatric Drug Intakes and Adverse Reactions
June 3, 2013
- 14 APIs/26 Products Including Third Domestic Biosimilar Receive Listing
June 3, 2013
- FDA Approves World’s First MEK Inhibitor Discovered by JT
May 31, 2013
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…